Certara, Inc. (NASDAQ:CERT) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 24.2% in the third quarter, Holdings Channel.com reports. The fund owned 20,260 shares of the company’s stock after purchasing an additional 3,948 shares during the period. SG Americas Securities LLC’s holdings in Certara were worth $237,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in CERT. Algert Global LLC acquired a new stake in Certara in the 2nd quarter valued at approximately $156,000. Select Equity Group L.P. grew its stake in shares of Certara by 19.6% in the second quarter. Select Equity Group L.P. now owns 159,008 shares of the company’s stock valued at $2,202,000 after buying an additional 26,095 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Certara by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after acquiring an additional 975 shares in the last quarter. Daventry Group LP boosted its holdings in Certara by 153.0% during the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after acquiring an additional 791,405 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Certara in the 2nd quarter valued at about $311,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CERT has been the topic of several research reports. KeyCorp reduced their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Barclays lowered their price objective on Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 15th. Robert W. Baird reduced their target price on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Finally, UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $17.08.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by company insiders.

Certara Price Performance

Shares of NASDAQ CERT opened at $11.20 on Tuesday. The stock’s 50-day simple moving average is $11.60 and its 200-day simple moving average is $14.33. The firm has a market capitalization of $1.80 billion, a PE ratio of -28.72, a price-to-earnings-growth ratio of 5.40 and a beta of 1.49. Certara, Inc. has a fifty-two week low of $10.35 and a fifty-two week high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company had revenue of $93.31 million for the quarter, compared to analyst estimates of $96.01 million. During the same period in the previous year, the business posted $0.10 EPS. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. As a group, equities research analysts forecast that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.